Favorable α-fetoprotein decrease as a prognostic surrogate in patients with hepatocellular carcinoma after radiofrequency ablation

Journal of Gastroenterology and Hepatology (Australia)

Volumn 25, Issue 3, 2010, Pages 605-612

  Tsai, Ming Chao ^a   Wang, Jing Houng ^a   Hung, Chao Hung ^a   Kee, Kwong Ming ^a   Yen, Yi Hao ^a   Lee, Chuan Mo ^a   Hu, Tsung Hui ^a   Chen, Chien Hung ^a   Lu, Sheng Nan ^a  

^a CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

Author keywords

Half life; Hepatocellular carcinoma; Radiofrequency ablation; fetoprotein

Indexed keywords

ALPHA FETOPROTEIN;

AGED; ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; FEMALE; HUMAN; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; RADIOFREQUENCY ABLATION; TREATMENT RESPONSE; ASPIRATION CYTOLOGY; BIOLOGICAL MONITORING; CANCER PROGNOSIS; DISEASE FREE SURVIVAL; DISEASE MARKER; FINE NEEDLE ASPIRATION BIOPSY; HUMAN TISSUE; TREATMENT OUTCOME;

EID: 77649197474     PISSN: 08159319     EISSN: 14401746     Source Type: Journal    
DOI: 10.1111/j.1440-1746.2009.06115.x     Document Type: Article

References (39)

1. El-Serag HB, Rudolph KL. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology 2007 132 : 2557 2576.
2. Bosch FX, Ribes J, Borras J. Epidemiology of primary liver cancer. Semin. Liver. Dis. 1999 19 : 271 285.
3. El-Serag HB, Marrero JA, Rudolph L, Reddy KR. Diagnosis and treatment of hepatocellular carcinoma. Gastroenterology 2008 134 : 1752 1763.
4. Bruix J, Sherman M. Management of hepatocellular carcinoma. Hepatology 2005 42 : 1208 1236.
5. Allgaier HP, Deibert P, Zuber I, Olschewski M, Blum HE. Percutaneous radiofrequency interstitial thermal ablation of small hepatocellular carcinoma. Lancet 1999 353 : 1676 1677.
6. Curley SA, Izzo F, Ellis LM, Nicolas Vauthey J, Vallone P. Radiofrequency ablation of hepatocellular cancer in 110 patients with cirrhosis. Ann. Surg. 2000 232 : 381 391.
7. Tateishi R, Shiina S, Teratani T et al. Percutaneous radiofrequency ablation for hepatocellular carcinoma. An analysis of 1000 cases. Cancer 2005 103 : 1201 1209. (Pubitemid 40328091)
8. Lin SM, Lin CJ, Lin CC, Hsu CW, Chen YC. Radiofrequency ablation improves prognosis compared with ethanol injection for hepatocellular carcinoma < or =4 cm. Gastroenterology 2004 127 : 1714 1723.
9. Lin SM, Lin CJ, Lin CC, Hsu CW, Chen YC. Randomised controlled trial comparing percutaneous radiofrequency thermal ablation, percutaneous ethanol injection, and percutaneous acetic acid injection to treat hepatocellular carcinoma of 3 cm or less. Gut 2005 54 : 1151 1156.
10. Bruix J, Sherman M, Llovet JM et al. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J. Hepatol. 2001 35 : 421 430.
11. Chen CJ, Lu SN, You SL et al. [Community-based hepatocellular carcinoma screening in seven townships in Taiwan]. J. Formos. Med. Assoc. 1995 94 (Suppl 2 S94 102.
12. Daniele B, Bencivenga A, Megna AS, Tinessa V. Alpha-fetoprotein and ultrasonography screening for hepatocellular carcinoma. Gastroenterology 2004 127 : S108 12.
13. Trevisani F, D'Intino PE, Morselli-Labate AM et al. Serum alpha-fetoprotein for diagnosis of hepatocellular carcinoma in patients with chronic liver disease: influence of HBsAg and anti-HCV status. J. Hepatol. 2001 34 : 570 575.
14. Zhou L, Liu J, Luo F. Serum tumor markers for detection of hepatocellular carcinoma. World. J. Gastroenterol. 2006 12 : 1175 1181.
15. Toyoda H, Kumada T, Osaki Y, Oka H, Kudo M. Role of tumor markers in assessment of tumor progression and prediction of outcomes in patients with hepatocellular carcinoma. Hepatol. Res. 2007 37 (Suppl 2 S166 71.
16. Gitlin D, Boesman M. Serum alpha-fetoprotein, albumin, and gamma-G-globulin in the human conceptus. J. Clin. Invest. 1966 45 : 1826 1838.
17. Han SJ, Yoo S, Choi SH, Hwang EH. Actual half-life of alpha-fetoprotein as a prognostic tool in pediatric malignant tumors. Pediatr. Surg. Int. 1997 12 : 599 602.
18. Bredow MT, Goldie DJ. Rapid falls in maternal serum alpha-fetoprotein concentrations. J. Clin. Pathol. 1985 38 : 473 474.
19. Johnson PJ, Williams R. Serum alpha-fetoprotein estimations and doubling time in hepatocellular carcinoma: influence of therapy and possible value in early detection. J. Natl. Cancer. Inst. 1980 64 : 1329 1332.
20. McIntire KR, Vogel CL, Princler GL, Patel IR. Serum alpha-fetoprotein as a biochemical marker for hepatocellular carcinoma. Cancer. Res. 1972 32 : 1941 1946.
21. Hsieh MY, Lu SN, Wang LY et al. Alpha-fetoprotein in patients with hepatocellular carcinoma after transcatheter arterial embolization. J. Gastroenterol. Hepatol. 1992 7 : 614 617.
22. Chan SL, Mo FK, Johnson PJ et al. New utility of an old marker: serial alpha-fetoprotein measurement in predicting radiologic response and survival of patients with hepatocellular carcinoma undergoing systemic chemotherapy. J. Clin. Oncol. 2009 27 : 446 452.
23. Kee KM, Wang JH, Lee CM et al. Validation of clinical AJCC/UICC TNM staging system for hepatocellular carcinoma: analysis of 5,613 cases from a medical center in southern Taiwan. Int. J. Cancer. 2007 120 : 2650 2655.
24. Hung CH, Lu SN, Wang JH et al. Correlation between ultrasonographic and pathologic diagnoses of hepatitis B and C virus-related cirrhosis. J. Gastroenterol. 2003 38 : 153 157.
25. Inanc SE, Meral R, Darendeliler E, Yasasever V, Onat H. Prognostic significance of marker half-life during chemotherapy in non-seminomatous germ cell testicular tumors. Acta. Oncol. 1999 38 : 505 509.
26. Buamah PK, James OF, Skillen AW, Harris AL. The value of tumour marker kinetics in the management of patients with primary hepatocellular carcinoma. J. Surg. Oncol. 1988 37 : 161 164.
27. Shirabe K, Takenaka K, Gion T, Shimada M, Fujiwara Y, Sugimachi K. Significance of alpha-fetoprotein levels for detection of early recurrence of hepatocellular carcinoma after hepatic resection. J. Surg. Oncol. 1997 64 : 143 146.
28. Chan SL, Mo FK, Johnson PJ et al. New utility of an old marker: serial {alpha}-fetoprotein measurement in predicting radiologic response and survival of patients with hepatocellular carcinoma undergoing systemic chemotherapy. J. Clin. Oncol. 2008.
29. Kurokohchi K, Hosomi N, Yoshitake A et al. Successful treatment of large-size advanced hepatocellular carcinoma by transarterial chemoembolization followed by the combination therapy of percutaneous ethanol-lipiodol injection and radiofrequency ablation. Oncol. Rep. 2006 16 : 1067 1070.
30. Veltri A, Moretto P, Doriguzzi A, Pagano E, Carrara G, Gandini G. Radiofrequency thermal ablation (RFA) after transarterial chemoembolization (TACE) as a combined therapy for unresectable non-early hepatocellular carcinoma (HCC). Eur. Radiol. 2006 16 : 661 669.
31. Murata S, Tajima H, Nakazawa K, Onozawa S, Kumita S, Nomura K. Initial experience of transcatheter arterial chemoembolization during portal vein occlusion for unresectable hepatocellular carcinoma with marked arterioportal shunts. Eur. Radiol. 2009 19 : 2016 2023.
32. Lam VW, Ng KK, Chok KS et al. Incomplete ablation after radiofrequency ablation of hepatocellular carcinoma: analysis of risk factors and prognostic factors. Ann. Surg. Oncol. 2008 15 : 782 790.
33. Zytoon AA, Ishii H, Murakami K et al. Recurrence-free survival after radiofrequency ablation of hepatocellular carcinoma. A registry report of the impact of risk factors on outcome. Jpn. J. Clin. Oncol. 2007 37 : 658 672.
34. Omata M, Tateishi R, Yoshida H, Shiina S. Treatment of hepatocellular carcinoma by percutaneous tumor ablation methods: ethanol injection therapy and radiofrequency ablation. Gastroenterology 2004 127 : S159 66.
35. Jansen MC, van Hillegersberg R, Chamuleau RA, van Delden OM, Gouma DJ, van Gulik TM. Outcome of regional and local ablative therapies for hepatocellular carcinoma: a collective review. Eur. J. Surg. Oncol. 2005 31 : 331 347.
36. Madsen AC, Rikkers LF. Alpha-fetoprotein secretion by injured and regenerating hepatocytes in the dog. J. Surg. Res. 1984 37 : 402 408.
37. Watanabe A, Shiota T, Hayashi S, Nagashima H. Serum alpha-fetoprotein in fulminant hepatitis and hepatic regeneration following partial hepatectomy. Biochem. Med. 1984 32 : 132 137.
38. Liaw YF, Tai DI, Chen TJ, Chu CM, Huang MJ. Alpha-fetoprotein changes in the course of chronic hepatitis: relation to bridging hepatic necrosis and hepatocellular carcinoma. Liver 1986 6 : 133 137.
39. Tateishi R, Shiina S, Yoshida H et al. Prediction of recurrence of hepatocellular carcinoma after curative ablation using three tumor markers. Hepatology 2006 44 : 1518 1527.